New hope for blood cancer patients: drug shows promise in controlling disease

NCT ID NCT00726232

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlarged spleen. The study was stopped early, but results helped show how ruxolitinib can manage these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOPROLIFERATIVE NEOPLASM (MPN)

Contacts and locations

Locations

Study site

Houston, Texas, 77030, United States
Study site

Bergamo, Italy
Study site

Florence, Italy
Study site

Pavia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.